F.D.A. Rejects Closely Watched Lung Cancer Drug From China
Key Points:
- The FDA rejected a cancer drug invented in China, marking a setback for a medicine seen as a symbol of China's growing influence in drug development.
- Summit Therapeutics, a Florida-based company that acquired U.S. rights from Chinese drugmaker Akeso Biopharma, disclosed the FDA's decision on Sunday.
- The drug was being considered for patients with advanced lung cancer and showed promise in trials for other cancers like colon, bladder, and breast tumors.
- The FDA's rejection was due to the drug not demonstrating a statistically significant improvement in overall survival in a global clinical trial, despite its success in delaying cancer progression.
- Summit argued that slow patient enrollment affected results and submitted additional analyses on longer-term outcomes, but these were insufficient to convince the FDA.